Cataracts are primarily caused by aging or gene mutations and are the leading cause of blindness globally. As the older population increases, the number of patients with a cataract is expected to grow rapidly. At present, cataract surgery to replace the lens with an artificial intraocular lens is the principal treatment method. However, surgery has several drawbacks, including economic burdens and complications such as inflammation, xerophthalmia, macular edema and posterior capsular opacification. Thus, developing an effective non‑surgical treatment strategy is beneficial to both patients and public health. Mechanistically, cataract formation may be due to various reasons but is primarily initiated and promoted by oxidative stress and is closely associated with crystallin aggregation. In the present review, the current research progress on anti‑cataract drugs, including antioxidants and protein aggregation inhibitors is examined. It summarizes strategies for preventing and treating cataract through cell apoptosis and protein aggregation inhibition while discussing their limitations and further prospects.
1 December 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: Atherosclerosis is the most common cause of cardiovascular diseases. Clinical studies indicate that loss-of-function ASGR1 (asialoglycoprotein receptor 1) is significantly associated with lower plasma cholesterol levels and reduces cardiovascular disease risk. However, the effect of ASGR1 on atherosclerosis remains incompletely understood; whether inhibition of ASGR1 causes liver injury remains controversial. Here, we comprehensively investigated the effects and the underlying molecular mechanisms of ASGR1 deficiency and overexpression on atherosclerosis and liver injury in mice. METHODS: We engineered Asgr1 knockout mice ( Asgr1−/− ), Asgr1 and ApoE double-knockout mice ( Asgr1−/−ApoE−/− ), and ASGR1-overexpressing mice on an ApoE−/− background and then fed them different diets to assess the role of ASGR1 in atherosclerosis and liver injury. RESULTS: After being fed a Western diet for 12 weeks, Asgr1−/−ApoE−/− mice exhibited significantly decreased atherosclerotic lesion areas in the aorta and aortic root sections, reduced plasma VLDL (very-low-density lipoprotein) cholesterol and LDL (low-density lipoprotein) cholesterol levels, decreased VLDL production, and increased fecal cholesterol contents. Conversely, ASGR1 overexpression in ApoE−/− mice increased atherosclerotic lesions in the aorta and aortic root sections, augmented plasma VLDL cholesterol and LDL cholesterol levels and VLDL production, and decreased fecal cholesterol contents. Mechanistically, ASGR1 deficiency reduced VLDL production by inhibiting the expression of MTTP (microsomal triglyceride transfer protein) and ANGPTL3 (angiopoietin-like protein 3)/ANGPTL8 (angiopoietin-like protein 8) but increasing LPL (lipoprotein lipase) activity, increased LDL uptake by increasing LDLR (LDL receptor) expression, and promoted cholesterol efflux through increasing expression of LXRα (liver X receptor-α), ABCA1 (ATP-binding cassette subfamily A member 1), ABCG5 (ATP-binding cassette subfamily G member 5), and CYP7A1 (cytochrome P450 family 7 subfamily A member 1). These underlying alterations were confirmed in ASGR1-overexpressing ApoE−/− mice. In addition, ASGR1 deficiency exacerbates liver injury in Western diet–induced Asgr1−/−ApoE−/− mice and high-fat diet–induced but not normal laboratory diet–induced and high-fat and high-cholesterol diet–induced Asgr1−/− mice, while its overexpression mitigates liver injury in Western diet–induced ASGR1-overexpressing ApoE−/− mice. CONCLUSIONS: Inhibition of ASGR1 inhibits atherosclerosis in Western diet–fed ApoE−/− mice, suggesting that inhibiting ASGR1 may serve as a novel therapeutic strategy to treat atherosclerosis and cardiovascular diseases.
24 December 2025 in Pharmacology Research & Perspectives
Paeonol (PAE), a phenolic phytochemical derived from traditional Chinese medicinal plants, exhibits multifaceted pharmacological properties including demonstrated antitumor efficacy against hepatic, gastric, and breast carcinomas. However, its therapeutic potential in glioma remains unexplored. Ferroptosis, a regulatory cell death pathway dependent on iron content mediated through lethal lipid peroxidation, has become a prospective method for targeted treatment of drug‐resistant malignant tumors. This study confirmed that PAE is a new inducer of ferroptosis in human glioma cells. Inhibition of glioma proliferation, migration, and invasion was observed. Mechanistically, PAE depletes lipid droplets (LDs) and amplifies cytotoxic lipid peroxides (LPO) and reactive oxygen species (ROS); caspase‐independent cell death was achieved. Crucially, ferroptosis inhibitors (ferrostatin‐1, α‐tocopherol) reversed PAE's antineoplastic roles, confirming pathway specificity. These findings position PAE as a dual‐action agent capable of simultaneously inducing ferroptosis and impeding metastatic spread, offering a mechanistically distinct approach to overcome temozolomide resistance in glioma therapeutics.
21 August 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: Vascular smooth muscle cell (VSMC) phenotypic modulation is responsible for the pathogenesis of hyper-muscularized arterial diseases. Recent studies have highlighted the critical role of epigenetic regulation in VSMC fate. However, the mechanisms underlying the precise regulation of the epigenetic machinery in VSMC remain unclear. METHODS: Using mouse aortic smooth muscle cells, carotid artery injury mouse model, and human atherosclerosis data sets, we identified GRK2 (G-protein–coupled receptor kinase 2) as a novel epigenetic regulator governing VSMC fate. RESULTS: GRK2 expression was found to be elevated in dedifferentiated VSMCs. Pharmacological or genetic silencing of GRK2 inhibited VSMC phenotypic switching. Mechanistic investigations demonstrated that GRK2 modulated VSMC phenotype via DNMT1 (DNA methyltransferase 1)-mediated DNA methylation. GRK2 phosphorylated DNMT1, stabilizing it by modulating its ubiquitination. Hypermethylated VSMC exhibited reduced expression of contractile-associated proteins. Inhibition of DNMT1 abolished the effects of GRK2 overexpression on VSMC phenotype, indicating a DNMT1-mediated mechanism. CONCLUSIONS: Our findings revealed that the GRK2-DNMT1 signaling axis is a critical regulator in VSMC phenotypic switching and present a potential therapeutic target for vascular remodeling.
Objectives: Automated blood cell detection from microscopic images is essential for routine hematological examination and computer-assisted laboratory diagnosis. However, accurate detection remains challenging because of the small size, dense distribution, overlap, and indistinct boundaries of blood cells. This study aimed to develop an efficient deep learning framework for accurate multi-class detection of blood cells in microscopic images. Methods: We developed BCG-YOLO, an enhanced detector based on YOLO11n that integrates a lightweight backbone network, an improved multi-scale feature fusion module, and a dynamic detection head to improve feature representation and adaptive detection of small and densely distributed blood cells. The proposed model was evaluated on the public BCCD dataset and compared with representative one-stage detectors, transformer-based methods, and real-time object detection models. Ablation studies were conducted to assess the effectiveness of each proposed component. Additional five-fold cross-validation and paired image-level bootstrap analyses were performed for YOLO11n and BCG-YOLO. Results: On the original fixed test split, BCG-YOLO achieved an mAP@0.5 of 95.3%, an mAP@0.5:0.95 of 67.6%, and a recall of 89.8% while requiring only 3.80 GFLOPs. Under the common training and evaluation protocol used in this study, BCG-YOLO achieved the best overall detection performance among all evaluated models. Ablation experiments further demonstrated the effectiveness of the proposed modules, confirming consistent improvements in overall detection performance and computational efficiency. Conclusions: BCG-YOLO provided a favorable balance between detection accuracy and computational cost in the internal evaluation on BCCD. These findings support its feasibility for microscopic blood-cell detection, while independent external validation is required to establish generalizability across laboratories, staining protocols, and imaging systems.
Background Psoriasis is a chronic, multisystem inflammatory disease with predominantly skin and joint involvement. The interleukin-(IL-)17 axis plays a vital role in the development of psoriasis. Secukinumab (Cosentyx) is a fully human monoclonal antibody that selectively targets IL-17A for the treatment of adult patients with psoriasis[1]. Objectives This study aimed to systematically evaluate the efficacy and safety of secukinumab therapy in psoriasis. Methods Eight databases (PubMed, Web of Science, Embase, Cochrane Library, Web of Knowledge, MEDLINE, Clinical Trials.gov, and FDA.gov) were searched for studies on secukinumab treatment of psoriasis published from the date of establishment of the database to January 3, 2022. A random effect model was used to conduct a meta-analysis of the efficacy and safety of abatacept in patients with RA using (Stata 12.0). Results A total of 27 studies with a total of 4470 patients were included. After receiving secukinumab therapy for 12 weeks, The response rate of PASI 75 was 82.2% (95% CI 0.766–0.879,p<0.01), PASI 90 was 66.3%(95% CI 0.609–0.718,p<0.01), and PASI 100 was 42% (95% CI 0.343–0.497,p<0.01). The results showed that more than 80% of patients achieved skin lesion removal in 12 weeks. Considering PGA 0/1 as the secondary endpoint. The percentage of patients who achieved a PGA score of 0 or 1 was 72.3% at 12 weeks (95% CI 0.658–0.788,p=0.005). As for the safety, the incidence of adverse events was 63.7%. Infection is the main adverse effects, with rates of 19.4%. Most of the adverse events were mild and recovered quickly after discontinuation. (Figure 1) Conclusion Secukinumab is effective in patients with psoriasis and is generally well tolerated, and thus represents a useful treatment alternative to TNFi and other bDMARDs in adult patients with psoriasis. Reference [1]Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483-94. Available evidence including patients with psoriasis treated with secukinumab. Efficacy of Secukinumab in patients with psoriasis (A) PASI 75 (B) PASI 90 (C) PASI 100 (D) PGA score of 0 or 1 Acknowledgements: NIL. Disclosure of Interests None Declared.